DRUG REGULATORY AUTHORITY OF PAKISTAN
Division of Quality Assurance and Laboratory Testing

RAPID ALERT

DRAP ALERT No: Nº I/S/11-04-51

Drug Products Declared as "Unregistered" by Central Drugs Laboratory (CDL), Karachi

Date:, 5th November, 2026

Target Audience:

- Field offices of DRAP and Provincial Drug Control departments.
- Healthcare Professionals
- Consumers

Problem Statement:

Central Drugs Laboratory (CDL), Karachi has declared the samples of below-mentioned drug products as "Unregistered". Following are the details:

Sr. No.	Name of product	Batch Number	Name of manufacturer	Remarks
1	**Flecainide Acetate 50mg Tablet**	FDAG020	Brown & Burk UK ltd. UK	CDL has declared the drug product as "Unregistered".
2	**Modafinil 200mg tablet**	MDSB25008A	Milpharm Limited, UK	CDL has declared the drug product as "Unregistered".
3	**Mysoline 250mg Compresse/Tablet**	4626	Laboratorio Farmaceutico SIT S.r.l Via Cavour, 70-27035 Mede (PV).	CDL has declared the drug product as "Unregistered".

Risk Statement:

The use of the above-mentioned **Unregistered** drug products may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.

Action Initiated:

The Regulatory Field Force of Provincial Drug Control Departments has been asked to conduct surveillance activities throughout the supply chain to confiscate the above-mentioned drug products.

DRAP, Islamabad + 92 051 9255969 gsms@dra.gov.pk

Advice for Healthcare Professionals:

DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers:

Consumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above-mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk